Targets › LMP2A
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jul 2031.
Open in Phaseline: the race on LMP2A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Baylor College of Medicine | TGFbeta resistant LMP-specific CTLs TGF-beta-resistant, LMP2A-specific cytotoxic T lymphocytes engineered to target EBV-associ | LMP2A | Phase 1 | Lymphoma | Jul 2031 |
Lymphoma (1)
protein or peptide (1)
Baylor College of Medicine (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.